Literature DB >> 27313432

Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist.

Lillian L Smith, Juan F Mosley, Crystal Parke, Jamal Brown, Lillian S Barris, Linh D Phan.   

Abstract

Dulaglutide (Trulicity): the third once-weekly GLP-1 agonist for type-2 diabetes.

Entities:  

Keywords:  dulaglutide; glucagon-like peptide; incretin mimetics; insulin secretion; type-2 diabetes

Year:  2016        PMID： 27313432      PMCID： PMC4894510     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  8 in total

1.  Monotherapy with the once-weekly GLP-1 analogue dulaglutide for 12 weeks in patients with Type 2 diabetes: dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study.

Authors:  G Grunberger; A Chang; G Garcia Soria; F T Botros; R Bsharat; Z Milicevic
Journal:  Diabet Med       Date:  2012-10       Impact factor: 4.359

2.  Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3).

Authors:  Guillermo Umpierrez; Santiago Tofé Povedano; Federico Pérez Manghi; Linda Shurzinske; Valeria Pechtner
Journal:  Diabetes Care       Date:  2014-05-19       Impact factor: 19.112

3.  Glycemic control in non-diabetic critically ill patients.

Authors:  Farnoosh Farrokhi; Dawn Smiley; Guillermo E Umpierrez
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2011-10       Impact factor: 4.690

4.  Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).

Authors:  Carol Wysham; Thomas Blevins; Richard Arakaki; Gildred Colon; Pedro Garcia; Charles Atisso; Debra Kuhstoss; Mark Lakshmanan
Journal:  Diabetes Care       Date:  2014-05-30       Impact factor: 19.112

5.  Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists!

Authors:  Stanley Schwartz; Ralph A DeFronzo
Journal:  Diabetes Care       Date:  2013-07       Impact factor: 19.112

Review 6.  Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.

Authors:  Alan J Garber
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

Review 7.  Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes.

Authors:  Krystal L Edwards; Molly G Minze
Journal:  Core Evid       Date:  2015-01-09

8.  Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).

Authors:  Michael Nauck; Ruth S Weinstock; Guillermo E Umpierrez; Bruno Guerci; Zachary Skrivanek; Zvonko Milicevic
Journal:  Diabetes Care       Date:  2014-04-17       Impact factor: 19.112
  8 in total
  5 in total

Review 1.  Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes.

Authors:  Seungah Lee; Dong Yun Lee
Journal:  Ann Pediatr Endocrinol Metab       Date:  2017-03-31

Review 2.  GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data.

Authors:  Andrei C Sposito; Otávio Berwanger; Luiz Sérgio F de Carvalho; José Francisco Kerr Saraiva
Journal:  Cardiovasc Diabetol       Date:  2018-12-13       Impact factor: 9.951

3.  No QTc Prolongation with Semaglutide: A Thorough QT Study in Healthy Subjects.

Authors:  Valentin Demmel; Anne Sandberg-Schaal; Jacob B Jacobsen; Georg Golor; Jonas Pettersson; Anne Flint
Journal:  Diabetes Ther       Date:  2018-05-24       Impact factor: 2.945

4.  Case Report of Acute Pancreatitis Associated With Combination Treatment of Dulaglutide and Glipizide.

Authors:  Oyedotun Babajide; Nabin K C; Isaac Solaimanzadeh; Zewge Shiferaw-Deribe
Journal:  Cureus       Date:  2022-01-04

Review 5.  Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care.

Authors:  Elpiniki Rentzeperi; Stavroula Pegiou; Theocharis Koufakis; Maria Grammatiki; Kalliopi Kotsa
Journal:  J Pers Med       Date:  2022-03-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.